At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Investors
 



Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Feb 26, 2015
Amicus Therapeutics to Present at Cowen and Company 35th Annual Health Care Conference

Feb 25, 2015
Amicus Therapeutics to Announce Full-Year 2014 Financial Results on March 3, 2015

View all »Events & Presentations

Mar 3, 2015 at 5:00 PM ET
Amicus Full-Year 2014 Results Conference Call and Webcast

Mar 2, 2015 at 4:50 PM ET
Cowen and Company 35th Annual Health Care Conference


Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy